培训班：
临床研究中最佳伦理规范的理解与实施

2011年12月13-14日
中国 · 北京 · 北京大学医学部

组委会主席

李海燕 教授
北京大学第三医院药物临床试验机构主任
北京大学临床研究所副所长

组委会成员

Beat E. WIDLER 博士 （主讲人）
欧洲临床质量保证和风险管理专家

刘海涛 医师，国际公共卫生学硕士
北京大学生物医学伦理委员会办公室主任

内容概览

针对临床研究中对专业化伦理规范培训需求的日益增长，本次培训课程将讲授临床试验中被国际广泛接受与要求的伦理标准。专家将结合临床实例对伦理指南及实施方面的各个环节进行详细阐述，并通过课堂练习及案例分析，与参会者积极互动、深入探讨。

授课内容

- 简介- 生物医学研究伦理发展与赫尔辛基宣言及ICH GCP
- 中国药物临床试验伦理要求
- 临床试验I-IV期（包括上市后观察性研究）受试者的保护
- 确保受试者权益的临床试验伦理审查过程
- 临床试验方案的伦理审查重点
- 正常成年受试者知情同意过程
- 对受试者须知及知情同意过程的审查重点
- 涉及弱势成人群体及儿童的临床试验伦理问题
- 关于伦理问题的案例分析
- 对参加临床试验受试者的支持及经济补偿的伦理考虑
- 临床试验研究完整性、伦理和社会责任

学习目标

- 更好地理解临床研究的伦理要求及影响
- 进一步熟悉GCP，ICH和SFDA新的伦理指导原则
- 遵循法规规范
- 提高临床研究设计能力，确保伦理的有效实施以符合检查和申报要求

参会人员

- 临床医务人员
- 临床项目负责人
- 医学事务负责人
- 法规事务人员
- 研发人员
- 卫生政策制定者

DIA 中国办公室
北京市朝阳区东三环北路霞光里18号佳程广场
A座11层1155室，邮编100027

DIA 全球办公室
美国 • 宾夕法尼亚 瑞士 • 巴塞尔 日本 • 东京
印度 • 孟买 中国 • 北京

主办单位：
药物信息协会

www.diahome.org

协办单位：
北京大学临床研究所

Peking University Clinical Research Institute

第一天 12月13日 • 星期二

7:30 – 8:30 会议注册

8:30 – 8:45 欢迎致辞

8:45 – 9:45

促使赫尔辛基宣言以及ICH GCP出台的生物医学科研伦理历史

学习目的

通过本节的介绍，学员将了解：

- 药物研发和药剂产品使用过程中的灾难性事件（如：萨力多胺事件）。如何促进临床试验的伦理概念以及涉及上市后药用产品的伦理实施的发展。
- 个人的卫生保健与优先研究领域之间的利益冲突是什么。
- 赫尔辛基宣言如何致力于协助医务人员解决为患者提供最佳治疗和进行人体标准化研究之间所产生的冲突。
- 在临床试验中使用安慰剂的时机和方式及如何从伦理上得以恰当释义。
- 在临床试验的伦理行为中，ICH GCP，美国和欧盟立法有什么样的影响和重要意义。
- 在中国进行临床试验时，国际指南和法规具有什么样的相关性和重要性。

9:45 - 10:20 小组讨论

10:20 – 10:40 茶歇

10:40 – 11:30

临床I期到IV期，包括上市后的观察性试验中对受试者保护

学习目的

通过本节的介绍，学员将了解：

- 在不同类型的试验机构中，研究者和申办方对保护受试者应承担的责任是什么。
- 在涉及健康志愿者、住院病人与非住院病人的临床试验中需考虑哪些因素。
- 文化背景及医疗形式与伦理的相关性。
- 临床设计方案与临床试验伦理行为的相关性。
- 其它影响伦理的因素（技术和设备、药品管理、人员培训等）。
- 有关责任、赔偿、保险以及数据保护和保密。
- 观察性研究中需关注哪些伦理方面的问题。
- 临床试验时所常见的伦理问题。

11:30 - 12:00 小组讨论

12:00 – 13:30 午餐 （赢家商务酒店 2层）

13:30 – 14:15

科研诚信，进行临床试验需要承担的伦理和社会责任以及出现差错时应当承担的道德责任

学习目的

通过本节的介绍，学员将了解：

- 临床试验中，研究者和申办方各应承担的社会责任和道德责任。
- 如何掌握患者临床数据的透明度。
- 如何处理临床研究中的严重质量问题。
- 发生争议与不良行为时所采取的措施。
- 如何妥善管理临床上出现的问题及确保研究的连续性。

14:15 - 14:30 小组讨论

14:30 - 15:00

确保可靠的受试者保护以及临床试验伦理行为的伦理审查过程

学习目的

通过本节的介绍，学员将了解：

- 伦理委员会进行伦理审查过程中的基本要素及其要求。
- 不同区域和国家伦理委员会对伦理问题解决的差异。

15:00 – 15:20 茶歇

15:20 – 16:15

小组练习：审查临床方案并识别其中的伦理问题

学习目的

案例研究将训练学员：

- 识别方案中容易出现的伦理问题。
- 识别试验中潜在的伦理挑战。
- 探索解决问题的策略。

16:15 – 17:00 小组讨论结果

17:00 第一天培训结束

第二天 12月14日 星期三

8:30 – 9:15

临床试验中，健康成年受试者的知情同意过程

学习目的

通过本节的介绍，学员将了解：

- 口头知情同意和书面知情同意各自涉及的原则是什么。
- 知情同意书和患者信息表必备的构成要素有哪些。
- 知情同意书和患者信息表的功能和内容是什么。
- 如何把握知情同意过程中所获得的信息。临床研究者所应承担的责任。
- 当使用视频资料、小组会议等形式时应当考虑哪些因素。
- 如何与不同教育层次和有语言障碍的患者进行沟通以及如何处理沟通中可能发生的冲突。

9:15 - 10:00

小组练习：患者信息表和知情同意过程评议

学习目的

案例研究将训练学员：

- 识别知情同意书、患者信息表或给患者的材料中所常出现的伦理问题。
- 理解知情同意过程中存在的伦理挑战。
- 探索解决问题的策略。

10:00 – 10:30 小组讨论结果

10:30 – 10:50 茶歇

10:50 – 12:00

弱势人群临床试验中的伦理问题

学习目的

通过本节的介绍，学员将了解：

- 弱势人群的定义
- 临床试验中如何对待不同类型的弱势人群，比如无意识的、有智障的、存在严重精神问题的或已无有效治疗结果的患者。
- 儿童临床试验应考虑的因素及采取的预防措施。
- 对军人、学生、囚犯等人群的临床试验应考虑的因素及采取的预防措施。
- 对不符卫生保健标准的贫困地区进行临床试验时应考虑的因素及采取的预防措施。

12:00 – 12:30 小组讨论

12:30 – 13:45 午餐 （赢家商务酒店 2层）

13:45 – 14:30

分组练习：通过案例分析，学员讨论相关的伦理问题及解决方法

学习目的

案例研究将着重培养学员：

- 识别临床试验/临床项目中的道德风险以及潜在的危险。
- 风险评估。
- 降低或预防风险的措施。

14:30 – 14:45 小组讨论结果

14:45 - 15:15

临床试验中的诱导因素

学习目的

通过本节的介绍，学员将了解：

- 与GCP和伦理要求相悖的诱导。
- 对临床试验参试者的补偿。
- 广告内容。
- 对向研究者推荐病人的医生的补偿。
- 对健康志愿者的补偿及支付方式。
- 服务中心参与受试者招募有可能导致的伦理问题。
- 如何应对社会媒体。

15:30 – 16:00 小组讨论

16:00 – 16:30 茶歇

16:30 – 17:00

中国临床试验的伦理要求

学习目的

通过本节的介绍，学员将了解：

- 药物临床试验伦理审查制度的建立。
- 对伦理要求的理解。

17:00 – 17:30 小组讨论

17:30 培训课程结束

Training Course:

Understanding and Implementing Best Ethics Practices in Clinical Research

December 13-14, 2011
Peking University Health Science Center • Beijing • China

PROGRAM CHAIRPERSON

Haiyan LI, Professor
Director,
Drug Clinical Trial Center, Peking University 3rd Hospital
Vice Director,
Peking University Clinical Research Institute

PROGRAM COMMITTEE

KEY INSTRUCTOR:
Beat E. WIDLER, PhD, dipl. Pharm. Med.
Europe Clinical QA & Risk Management Expert

Haitao LIU, MD, Master of International Public Health
Director, IRB Office, Peking University Clinical Research Institute

WHO SHOULD ATTEND

- Medical professionals
- Clinical project managers, directors, group leaders
- Clinical trial/study site investigators
- Medical affairs professionals and medical directors
- Regulatory affairs professionals
- R&D scientists
- Public health policy makers

DIA China
Gateway Plaza, Tower A, Room 1155, 18 XiaGuangLi, North Road, East Third Ring, Chaoyang District, Beijing 100027, China

DIA Regional Offices
Horsham, USA Basel, Switzerland Tokyo, Japan
Mumbai, India Beijing, China

With the continually increase of clinical studies in China, ethical considerations and good practices in clinical research and studies have received more attention by regulators, investigators/practitioners, and study sponsors. Good ethics practice plays an important role in both protecting and benefiting patients through medical and pharmaceutical science and technology development.

This two-day training course is an interactive forum that provides in-depth knowledge, international and China regulatory guidelines, and practical solutions to assist participants to gain a better understanding of the ethical requirement and to implement best ethics practices in clinical research. The course is designed by subject matter experts with examples from real-life experience. The instructors will compare Chinese requirements and ICH/European/US requirements with special focus on ethical review, the informed consent process, and risk management.

FEATURED TOPICS

- The history of biomedical research ethics leading to the Declaration of Helsinki and ICH GCP
- Ethical requirements for clinical trials in China
- Patient protection in clinical trials from Phase I to Phase IV, including post marketing observational trials
- The ethical review process to ensure reliable patient protection and ethical conduct of clinical trials
- Identifying ethically critical aspects of a protocol provided for review
- The Informed Consent Process in trials with conscious, adult participants
- Critical review of a Patient Information Sheet and the informed consent process.
- Ethical issues in clinical trials involving vulnerable adult populations and children
- Different case studies are presented and the participants are asked to identify what the ethical issues are and how these can be addressed
- When support to and compensation of patients in clinical trials becomes inducement
- Research integrity, ethics and social responsibility when conducting clinical trials and ethical responsibilities when things go wrong

LEARNING OBJECTIVES

- A Better understanding of the ethics requirement and impacts in conducting clinical research
- A Better understanding of GCP, ICH and SFDA new guideline for ethics
- Be in compliance with regulations
- Be able to design good clinical studies with good ethics practices to ensure successful compliance inspections and regulatory submissions

Host By:
Drug Information Association
www.diahome.org

Co-Sponsor:
Peking University Clinical Research Institute
PUCRI
Peking University Clinical Research Institute

DAY 1 | **TUESDAY, DECEMBER 13**

7:30 – 8:30 REGISTRATION

8:30 – 8:45 WELCOME AND INTRODUCTION

8:45 - 9:45

THE HISTORY OF BIOMEDICAL RESEARCH ETHICS LEADING TO THE DECLARATION OF HELSINKI AND ICH GCP

Learning Goal

At the end of this presentation participants will understand:

- How disasters in drug development and in the commercial use of pharmaceutical products and devices (e.g. thalidomide disaster) have shaped the development of ethical concepts for clinical trials and ethical behaviors once a medicinal product is commercialized.
- What the conflict of interest between individual health care and research priorities are.
- How the Declaration of Helsinki aims at helping physicians to overcome the conflict between providing best treatment to the individual patient versus performance of standardized research for the benefit of mankind.
- How and when the use of placebo in a clinical trial can morally and ethically be justified.
- What has been the impact and significance of ICH GCP, US and EU legislation on the ethical conduct of clinical trials.
- What the relevance and significance of international guidelines and rules are on the conduct of clinical trials in China.

9:45 - 10:20 GROUP DISCUSSION

10:20 – 10:40 COFFEE BREAK

10:40 – 11:30

PATIENT PROTECTION IN CLINICAL TRIALS FROM PHASE I TO PHASE IV, INCLUDING POST MARKETING OBSERVATIONAL TRIALS

Learning Goal

At the end of this presentation participants will understand:

- What the investigator's and sponsor's responsibility for optimal patient protection in different types of trial set-ups are
- What must be considered when a clinical trial is conducted in healthy volunteers' versus patients, hospitalized versus out-patients.
- How cultural behaviors and the way medicine is practiced can impact on ethics.
- How a properly designed, planned and implemented protocol determines the ethical conduct of a clinical trial.
- How technical and logistic aspects such as labeling / reconstitution and administration of IMP (Investigational Medicinal Product, adequate facilities, staffing and training of all those involved in a clinical trial impact ethics
- What one needs to know about liability, indemnity and insurance as well as data protection and confidentiality.
- What ethical considerations are to be made when conducting observational studiers
- What are common pitfalls from an ethics perspective when performing a clinical trial.

11:30 - 12:00 GROUP DISCUSSION

12:00 – 13:30 LUNCH BREAK **(Yingjia Hotel 2F)**

13:30 – 14:15

RESEARCH INTEGRITY, ETHICS AND SOCIAL RESPONSIBILITY WHEN CONDUCTING CLINICAL TRIALS AND ETHICAL RESPONSIBILITIES WHEN THINGS GO WRONG

Learning Goal

At the end of this presentation participants will understand:

- What the societal and morale responsibilities are of an investigator and sponsor when conducting a clinical trial.
- Transparency and disclosure and access to patient level data.
- How to act when serious quality issues occur.
- How to act when misconduct is suspected and confirmed.
- How to ensure adequate issue management and business continuity.

14:15 - 14:30 GROUP DISCUSSION

14:30 - 15:00

THE ETHICAL REVIEW PROCESS TO ENSURE RELIABLE PATIENT PROTECTION AND ETHICAL CONDUCT OF CLINICAL TRIALS

Learning Goal

At the end of this presentation participants will understand:

- What the basic elements of the ethical review process by ethics committees and their requirements are.
- How approaches, concepts and processes of ethics committee organization and ethical review differ between regions and countries.

15:00 –15:20 COFFEE BREAK

15:20 – 16:15

EXERCISE: GROUP WORK TO IDENTIFY THE ETHICALLY CRITICAL ASPECTS IN A PROTOCOL PROVIDED FOR REVIEW.

Learning Goal

The case study shall train participants in:

- Recognizing ethics pitfalls in a protocol.
- Identifying trial aspects that represent a possible ethics challenge.
- Develop mitigating and preventive strategies.

16:15 – 17:00

COMMON REVIEW OF THE GROUP WORK FINDINGS

17:00 END OF DAY 1

DAY 2 | **WEDNESDAY, DECEMBER 14**

8:30 – 9:15

THE INFORMED CONSENT PROCESS IN TRIALS WITH CONSCIOUS, ADULT PARTICIPANTS

Learning Goal
At the end of this presentation participants will understand:
- What the principles of oral and written information to patients are.
- What the essential elements of a Informed Consent Form and Patient Information Sheet are.
- What the role and content of the Informed Consent Form and the Patient Information Sheet are.
- How the overall information and consent process should be handled and which tasks can or cannot be delegated by the investigator.
- What needs to be considered when using didactic tools such as videos, group meetings.
- How to deal with illiterate patients.
- How to deal with literate patients but who do not read and speak the local language
- What the investigator's responsibilities and possible conflicts of interest in this process are.

9:15 - 10:00

EXERCISE: GROUP WORK: CRITICAL REVIEW OF A PATIENT INFORMATION SHEET AND THE INFORMED CONSENT PROCESS

Learning Goal
The case study shall train participants in:
- Recognizing ethics pitfalls in a Informed Consent Form and Patient Information Sheet as well as other material given to patients.
- Identifying ethics challenges in the consent process.
- Develop mitigating and preventive strategies.

10:00 - 10:30

COMMON REVIEW OF THE GROUP WORK FINDINGS

10:30 – 10:50 COFFEE BREAK

10:50 – 12:00

ETHICAL ISSUES IN CLINICAL TRIALS INVOLVING VULNERABLE POPULATIONS

Learning Goal
At the end of this presentation participants will understand:
- What vulnerable patients are.
- How to deal with different types of vulnerable patients such as patients who are unconscious when entered into a clinical trial, are mentally impaired, suffer from a severe psychiatric condition or have exhausted treatment options.
- What are the special conditions and precautions when conducting clinical trials in children.
- What are the special conditions and precautions when conducting or entering patients in a clinical trial who are in a dependent situation like soldiers, students, prisoners
- What are the special conditions and precautions when conducting clinical trials in a geographical area where the health care system is substandard or where there is a prevalence of poverty.

12:00 - 12:30 GROUP DISCUSSION

12:30 – 13:45 LUNCH BREAK **(Yingjia Hotel 2F)**

13:45 – 14:30

EXERCISE: GROUP WORK: DIFFERENT CASE STUDIES ARE PRESENTED AND THE PARTICIPANTS ARE ASKED TO IDENTIFY WHAT THE ETHICAL ISSUES ARE AND HOW THESE CAN BE ADDRESSED

Learning Goal
At the end of this presentation participants will understand:
- Identifying ethics risks and pitfalls in a clinical trial / a clinical program.
- Assessing the magnitude of risks identified.
- Defining mitigating and preventive action.

14:30 – 14:45

COMMON REVIEW OF THE GROUP WORK FINDINGS

14:45 - 15:15

INDUCEMENT IN CLINICAL TRIALS

Learning Goal
At the end of this presentation participants will understand:
- What are inducements that are contrary to GCP and ethics
- How clinical trial participants can be reimbursed for incurred costs such as travel expense, loss of income because of scheduled clinic visits.
- What can be stated in an advertisement
- What compensation, if any, can be given to another physician for referring patients to the investigator.
- When compensation paid to healthy volunteers becomes unethical.
- How compensation should be paid to healthy volunteers.
- What ethics risk could arise when a call center is involved in recruitment or randomization of patients
- How to deal with social media

15:15 - 15:45 GROUP DISCUSSION

15:45 –16:00 COFFEE BREAK

16:00 – 17:00

ETHICAL REQUIREMENTS FOR CLINICAL TRIALS IN CHINA

Learning Goal
At the end of this presentation participants will understand:
- How in China the approach and thinking about ethics in clinical trials and commercialization of medicinal products has evolved and developed.
- What are the current ethical requirements in China.

17:00 - 17:30 GROUP DISCUSSION

17:30 END OF THE TRAINING COURSE

培训班：临床研究中最佳伦理规范的理解与实施

会议编码：#11980 • 2011年12月13-14日

中国 • 北京

会议场所：

北京大学医学部逸夫教学楼209会议室
北京市海淀区学院路38号，邮编：100191

联系方式：

会议咨询：请与谢飞先生联系
DIA 中国办公室，北京市朝阳区东三环北路霞光里18号佳程广场A座11层1155室。邮编：100027
电话：+86 10 5923 1222　　传真：+86 10 5923 1180
E-mail: fei.xie@diachina.org

取消注册：须在2011年12月6日前（含12月6日）

1. 凡已注册并付款者，在2011年12月6日之前取消注册，须按注册规定扣除手续费RMB500
2. 凡已注册并付款者，若逾期未确认取消或未参加培训者， 其缴纳的注册全额将不予退还
3. 凡已注册但未付款者，在2011年12月6日之前取消注册，须按注册规定缴纳手续费RMB500
4. 凡已注册但未付款者，若逾期未确认取消或未参加培训，仍须按注册规定全额缴纳注册费
5. 参会注册者应自行取消住宿预订及差旅订票等
6. 取消注册必须进行书面确认（Email 或传真）

预了解更多DIA会议信息
可登录 www.diachina.org，或 **点击此处**

会议注册费（含茶歇、午餐及会议资料）

企业	会员价	推荐 新会员价（会员费+会议费）	非会员价
提前注册（10月21日–11月30日）	RMB2000☐	RMB2880☐	RMB2880☐
标准价格（12月01日–12月07日）	RMB2500☐	RMB3380☐	RMB3380☐
现场注册（12月08日–12月14日）	RMB3000☐	RMB3880☐	RMB3880☐
政府机构/学术机构(全职人员)	RMB1600 ☐	RMB2480☐	RMB2480☐

* DIA推荐非会员参会者以 新会员价格 注册。加入DIA，将在一年有效期内享受DIA会员服务及会议优惠

☐ 索取发票（如需发票，请填写以下信息）

发票抬头 _____

发票金额　人民币 _____

服务项目　☐ 会议费　☐ 服务费

收件人地址 _____

_____

收件人姓名 _____

联系电话 _____

参会者信息（必填） _____

（参会者姓名、付款方式）_____

_____

_____

***注意：**

1. **您需要详细填写以上内容。款项入账并确认无误后，开具发票并邮寄**
2. **公司统一付款或团体注册：需将全部参会人姓名填写到参会者信息栏**

付款方式（本次会议仅接受银行汇款，汇率以中国人民银行当日外汇牌价为准）

请即付人民币_____　　会议编码 #11980
银行帐号：333757195112
开 户 行：中国银行北京市朝阳支行营业部
银行地址：北京市朝阳区东三环北路霞光里18号佳程广场A座一层
收 款 人：迪亚恩（北京）医药信息咨询有限公司
SWIFT ：BKCH CN BJ 110

***注意：**

早期优惠价格注册：2011年11月30日前付款

标准注册：2011年12月7日前付款

单位类别　☐ 药企　☐ 政府部门　☐ 科研院校　☐ 实验室/CRO　☐ 医疗机构（医院/诊所）　☐ 咨询公司　☐ 其它

请填写下表并保持字迹清晰

姓 _____ 名 _____ 职位 _____　　性别：☐ 先生　☐ 女士

单位（公司）名称（英文）_____

中文地址（请注明地址以便今后能正确邮寄）_____

英文地址 _____

省份及城市_____ 国家 _____ 邮政编码 _____ ☐ 公司地址 ☐ 家庭地址

电话 _____ 传真 _____ 手机 _____

电子邮件（必填，以便通过电子邮件发送确认）_____

如果您传真或邮寄报名表，请提供您的名片或名片复印件

Training Course: Understanding and Implementing Best Ethics Practices in Clinical Research

Event I.D. # 11980 – December 13-14, 2011

Beijing, CHINA

TRAVEL AND HOTEL
Conference Room #209, Yifu Teaching Building , Peking University Health Science Center
Xueyuan Rd., Haidian District, Beijing, China, 100191

DRUG INFORMATION ASSOCIATION CHINA OFFICE
Gateway Plaza, Tower A, Room 1155, 18 XiaGuangLi, North Road, East Third Ring, Chaoyang District, Beijing, 100027, China

Tel: +86-10-59231222 Fax: +86-10-59231180

Email: fei.xie@diachina.org

CANCELLATION POLICY: ON OR BEFORE DECEMBER 6, 2011

Cancellations must be made in writing and received by **December 6, 2011,** in order to receive a full refund minus the administrative fee of Member = RMB 500 Nonmember = RMB 500, before the cancellation date. Registrants who do not cancel in writing by the deadline date and do not attend the event will be responsible for paying the full registration fee. Registrants are also responsible for cancelling their own hotel and airline reservations. DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

For more meeting details
Please visit www.diachina.org OR Click here.

REGISTRATION FEES FOR CONFERENCE (*Registration fee includes Coffee Breaks, luncheons*)

INDUSTRY		MEMBER	NEW MEMBER PACKAGE	NONMEMBER
Industry Early-bird*	(Oct 21 - Nov 30)	RMB2000☐	RMB2880☐	RMB2880☐
Industry Standard	(Dec 01 - Dec 07)	RMB2500☐	RMB3380☐	RMB3380☐
Industry Onsite	(Dec 08 - Dec 14)	RMB3000☐	RMB3880☐	RMB3880☐
NONPROFIT/ACADEMIA/GOVERNMENT (Full-time)		RMB1600 ☐	RMB2480☐	RMB2480☐

* It is highly recommended nonmember attendees register the event with ***New Member Package*** (Meeting fee + 1 Year Membership Fee)
Join DIA now to qualify for the member service and discount!

☐ REQUEST CHINESE OFFICIAL INVOICE (FA PIAO)

If you need a chinese official invoice, Please complete following question

Invoice Title _____

Amount Charged RMB _____

Service Item ☐ Meeting Fee ☐ Training Fee

Recipient Address _____

_____

Recipient _____

Phone _____

Participants Information

_____

_____

_____

_____

Note: please list all participants' names, payment method and amount. After we confirmed payment, we will make invoice and send to you

PAYMENT (Bank Transfer Only)

Payment in the amount of RMB_____ Meeting I.D. #11980

Bank Account: 333757195112

Bank Name: Bank of China, Beijing Chaoyang Sub-branch Banking Dept.

Bank Address: 1st Floor, Tower A, Gateway, No.18 Xiaguangli, North Road, East Third Ring, Chaoyang District, Beijing, 100027, P.R.China

Payee: DIA (Beijing) Healthcare Information Consulting Limited

SWIFT Code: BKCH CN BJ 110

Please check the applicable category: ❑ Industry ❑ Government ❑ University ❑ CRO ❑ Hospital/Medical Practice ❑ Independent Consulatnt ❑ Other

PLEASE PRINT ALL INFORMATION CLEARLY

Last Name First Name M.I. Full Name in Chinese (If applicable) Please check one: ❑ Mr. ❑ Ms.

Job Title Affiliation (Company) ❑ Business Address ❑ Home Address

Address (Please write your address in the format required for delivery to your country.) City Postal Country

Address in Chinese (If applicable)

Telephone Number Fax Number Mobile Number

email (Required for confirmation)

IF FAXING OR MAILING THIS FORM, PLEASE PROVIDE A COPY OF REGISTRANT'S BUSINESS CARD.

DIA中国培训班：临床研究中最佳伦理规范的理解与实施
Training Course: Understanding and Implementing Best Ethics Practices in Clinical Research
协办单位：北京大学临床研究所
Co-Sponsor: Peking University Clinical Research Institute (PUCRI)

赢家商务酒店预订表

截止日期： 2011年12月12日
Deadline Date: December 12, 2011
将此表发至预订邮箱：yjswjd2009@sina.com
酒店地址：北京市海淀区学院路38号北京大学医学部院内

酒店信息及房价：见第三页 （会议注册费不包含住宿费用）
Hotel Info & Room Rate: Please see the 2nd page (Training registration fee does not include accommodation)

序号 No.	姓名 Name	单价及房型（大床/双床） Unit Price & Room Type （Kingsize / Twinsize）	入住日期 Check-In	离店日期 Check-Out
1		☐RMB 238 标准间（不含早，免费上网）		
		☐RMB 328 商务间（含单早，免费上网）		
2		☐RMB 238 标准间（不含早，免费上网）		
		☐RMB 328 商务间（含单早，免费上网）		

联系人 Contact：_____ 移动电话 Mobile：_____

特殊要求（如：到店时间、是否无烟房）：

Special Request (i.e. Arrival Time, Non-Smoking Room): _____

发送此表后，请拨打赢家商务酒店预订电话：010-82805379或010-82320101转预定部确认。

客人签名：_____

DIA中国培训班：临床研究中最佳伦理规范的理解与实施
Training Course: Understanding and Implementing Best Ethics Practices in Clinical Research
协办单位：北京大学临床研究所
Co-Sponsor: Peking University Clinical Research Institute (PUCRI)

唯实国际文化交流中心住宿预订表

截止日期：2011年12月12日
Deadline Date: December 12, 2011
请回传至 Please fax to：**+86 10 62308818**
酒店地址：北京市海淀区学院路39号北航东门往南200米

酒店信息及房价：见第三页 （会议注册费不包含住宿费用）
Hotel Info & Room Rate: Please see the 2nd page (Training registration fee does not include accommodation)

序号 No.	姓名 Name	单价及房型 （大床/双床） Unit Price & Room Type （Kingsize / Twinsize）	入住日期 Check-In	离店日期 Check-Out
1		☐RMB 488 商务标准间（含单早，免费上网）		
		☐RMB 578 豪华标准间（含单早，免费上网）		
2		☐RMB 488 商务标准间（含单早，免费上网）		
		☐RMB 578 豪华标准间（含单早，免费上网）		

联系人 Contact：_____ 移动电话 Mobile：_____

特殊要求（如：到店时间、是否无烟房）：

Special Request (i.e. Arrival Time, Non-Smoking Room): _____

如需唯实酒店的书面确认，请提供以下信息（两者选一即可）：

您的传真：_____ 您的电子邮箱：_____

客人签名：_____

DIA 中国伦理培训地点附近住宿

酒店	住宿	地址	电话/传真	乘车路线
赢家商务酒店 （北医的内部价）	标准间 RMB 238 （不含早，免费上网） 商务间 RMB 328 （含单早，免费上网）	北京市海淀区学院路 38 号北京大学医学部院内	电话：82320101 传真：82327676	北医校园内（见地图一）
唯实国际文化交流中心 （北医的内部价）	豪华标准间 RMB 578 （含单早，免费上网） 商务标准间 RMB 488 （含单早，免费上网）	北京市海淀区学院路 39 号北航东门往南 200 米	电话：62308899 传真：62308818	步行 0.5 公里（见地图二）

地图一：赢家商务酒店到北医逸夫楼的路线图



地图二：唯实酒店到北医逸夫楼的路线图